CA
NZ
UK
AU
IND
US
● LianBio was built to in-license and develop therapies for the Greater China and broader Asian markets, assembling a portfolio that included the cardiovascular drug mavacamten and other candidates licensed from Western partners.
A near-flatTrading sessioncan hide a surprisingly eventful corporate story. Lunai Bioworks Inc. (NASDAQ:LNAI) barely moved in its most recent session, yet the company behind the ticker has been anything but static: a fresh name, a reverse stock split, a blood-brain-barrierAcquisitionand new research collaborations have …
ChromoCure, Inc (OTC:KKUR) sits at the far, speculative edge of the health-technology market: a nano-cap over-the-counter security quoted at a small fraction of a penny. There is no confirmed recent catalyst, no verifiable stream of company news, and very little public financial disclosure to …
After a turbulent stretch, Keros Therapeutics (NASDAQ: KROS) has become a study in strategic focus. The clinical-stage biopharmaceutical company spent much of 2025 reshaping its pipeline and leadership, and it enters the autumn of 2026 as a leaner developer concentrated on a single lead …
● The pullback is consistent with the everydayVolatilityof a small clinical-stage biotech rather than any confirmed setback.
● Founded in 1993 and headquartered in San Francisco, the company adopted the Kyntra Bio name in January 2026 following what management described as a transformational 2025 that included the sale of its FibroGen China business,Debtrepayment and rebranding.
Few life-sciences tools companies are mid-transformation quite as dramatically as Standard BioTools. The proteomics and genomics instrument maker has spent 2026 negotiating its way toward a sweeping all-stock combination, and its shares, trading around $0.73 with a marketCapitalizationnear $285 million, recently ticked higher by …
● The recent 2% decline does not trace to a specific negative catalyst; rather, it fits the normal give-and-take in a stock that has rallied strongly.
Some tickers linger on trading screens long after the businesses behind them have faded, and Isodiol International Inc (OTC:ISOLF) looks like one of them. The supplied headline describes shares "holding steady" and asks what could "break the deadlock." The more accurate description is a …
● Clinical-stage oncology names rarely trade on fundamentals alone, and Janux Therapeutics has been no exception through 2026.
Please wait processing your request...